Albert Cha, M.D., Ph.D. is a Managing Partner at Vivo Ventures.. Albert invests in private and public biopharmaceutical and medical device companies. Albert draws on his scientific, medical, and operating experience when working with his portfolio companies.. Albert was an investor in Neomend (acquired by Bard), Vicept Therapeutics (acquired. by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica).. Albert was also involved in founding NextWave Pharmaceuticals and Prestwick Pharmaceuticals. Other investments include MEI Pharma (MEIP), YM Biosciences (YMI, acquired by Gilead Sciences), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG).. Albert currently serves on the board of several private biopharmaceutical and medical device companies. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.. Albert received his B.S. and M.S. in Electrical Engineering from Stanford University.. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.. During his studies, he was elected to Alpha Omega Alpha and won the prestigious Outstanding Graduate Student Award. His research in molecular biophysics has been published in highly respected journals such as Nature and Neuron.
